Our aim was to examine the effect of and polymorphisms on warfarin dose requirements in Turkish patients. 24 warfarin prescribed patients were included and analyzed for eight and 6 polymorphisms in the study. Patients with *1/*1 and -1639 GG and GA genotypes required higher warfarin doses in comparison to wild type genotype. Patients with *1/*3 and -1639 GG genotypes simultaneously, required the lowest dose of warfarin (4.64 mg/day). Patients with *1/*1 and 9041 AA genotype were found to require higher warfarin doses. Our results provide additional evidence to support the hypothesis that *2, *3, 9041 G > A polymorphisms explain considerable proportion of inter-individual variability in warfarin dose requirement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fca-2020-0027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Application of rapid genotyping of Warfarin individualized pharmacogenetic variants in Warfarin therapy.
Sci Rep
December 2024
Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China.
Warfarin is the most widely used oral anticoagulant in clinical practice. The cytochrome P450 2C9 (CYP2C9), vitamin K epoxide reductase complex 1 (VKORC1), and cytochrome P450 4F2 (CYP4F2) genotypes are associated with warfarin dose requirements in China. Accurate genotyping is vital for obtaining reliable genotype-guided warfarin dosing information.
View Article and Find Full Text PDFValue of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.
Clin Pharmacol Ther
January 2025
Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.
Implementation of pharmacogenetic testing in clinical care has been slow and with few exceptions is hindered by the lack of real-world evidence on how to best target testing. In this retrospective register-based study, we analyzed a nationwide cohort of 1,425,000 patients discharged from internal medicine or surgical wards and a cohort of 2,178 university hospital patients for purchases and prescriptions of pharmacogenetically actionable drugs. Pharmacogenetic variants were obtained from whole genome genotype data for a subset (n = 930) of the university hospital patients.
View Article and Find Full Text PDFVkorc1 polymorphisms of the Norway rats in China: Implications for rodent management and evolutionary origin of anticoagulant resistance mutations.
Sci Total Environ
December 2024
State Key Laboratory for Biology of Plant Diseases and Insect Pests, Institute of Plant Protection, Chinese Academy of Agricultural Sciences, Beijing 100193, China. Electronic address:
Article Synopsis
- The rise in use of second-generation anticoagulant rodenticides (SGARs) has sparked concerns about their safety for non-target animals and environmental effects.
- Research has identified specific mutations in the Vkorc1 gene that lead to anticoagulant resistance in Norway rats, particularly noting three mutations (A26T, C96Y, A140T) found in rat populations across China.
- Understanding these mutations and their origins can help in developing more effective rodent control strategies, emphasizing the need to adopt less toxic first-generation anticoagulant rodenticides (FGARs) in susceptible areas.
Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry.
Blood Adv
October 2024
Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
Article Synopsis
- Warfarin dosing is affected by individual clinical and genetic factors, with a need to explore genetic variants specific to African populations for better dosing guidance.
- A genome-wide association study (GWAS) focused on 989 warfarin-treated participants from Uganda, South Africa, and Zimbabwe, as well as African American cohorts, found significant genetic variants associated with warfarin response.
- The study highlighted the importance of the CYP2C9 and VKORC1 genes and identified a new potential genetic locus (MALL) that may impact warfarin response, warranting further research to understand its biological relevance.
Effect of genetic factors on the interindividual variability of warfarin dosage requirements in Japanese patients after adjusting for renal function.
Pharmazie
August 2024
Laboratory of Clinical Pharmacy, Faculty of Pharmacy, Takasaki University of Health and Welfare; Education Center for Clinical Pharmacy, Faculty of Pharmacy, Takasaki University of Health and Welfare.
Renal function significantly influences the appropriate warfarin dosage. However, studies investigating the impact of genetic factors on warfarin dosage, considering renal function, are limited. This study aimed to assess the role of genetic polymorphisms in , , , , , and in warfarin dosage adjustment considering renal function.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!